Navigation Links
TB -- hiding in plain sight
Date:5/21/2009

Stockholm, Sweden and Addis Ababa, Ethiopia Current research suggests that Mycobacterium tuberculosis can evade the immune response. The related report by Rahman et al, "Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions," appears in the June 2009 issue of The American Journal of Pathology.

More than two million people worldwide die from tuberculosis infection every year. Due in part to inappropriate antibiotic usage, there are a rising number (0.5 million in 2007) of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) tuberculosis. New therapies are needed to treat these dangerous infections.

Immune responses to tuberculosis rarely result in complete eradication of the infection. Instead, TB-infected immune cells promote the generation of chronic inflammation and the formation of granulomas, which are areas where the bacteria are contained but not destroyed. A group led by Dr. Susanna Grundstrom Brighenti at the Karolinska Institutet in Stockholm, Sweden therefore examined the immune response in patients infected with tuberculosis. This is the first study describing the immunoregulatory mechanism associated with the development of clinical disease at the site of infection in human TB. They found that while the immune cells responsible for killing the tuberculosis bacteria surrounded the granuloma, these cells had low levels of the molecules necessary to kill the TB. Instead, granulomas had high numbers of regulatory immune cells. These regulatory cells suppress the immune response, resulting in the survival of the tuberculosis bacteria and perhaps contributing to persistent long-term infection.

This study by Rahman et al "provide[s] evidence that the adaptive immune response in establishment of clinical TB [is] skewed towards a suppressive or regulatory phenotype that may inhibit proper immune activation and down-regulate the host response at the local site of infection. Compartmentalization of the immune response in human TB could be part of the reason why infection is never completely eradicated but instead develops into a chronic disease." In future studies, Dr. Grundstrom Brighenti and colleagues plan to "pursue new strategies developed to enhance cell-mediated immune responses that are known to provide protective immunity in patients with TB. Such an approach may involve targeting of certain subpopulations of immune cells with anti-inflammatory or immunoregulatory properties."


'/>"/>

Contact: Angela Colmone
acolmone@asip.org
301-634-7953
American Journal of Pathology
Source:Eurekalert  

Related biology news :

1. No hiding place for infecting bacteria
2. Using dominance to explain dog behavior is old hat
3. Disappearing act of worlds second largest fish explained
4. CSHL researchers explain process by which cells hide potentially dangerous DNA segments
5. New evidence explains poor infant immune response to certain vaccines, says MU researcher
6. Computer simulations explain the limitations of working memory
7. Gene linked to lupus might explain gender difference in disease risk
8. Difference in fat storage may explain lower rate of liver disease in African-Americans
9. Unexplained chest pain can be due to stress
10. Fish guts explain marine carbon cycle mystery
11. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TB -- hiding in plain sight
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... 28, 2017 Sangamo Therapeutics, Inc. (NASDAQ: ... reported its fourth quarter and full year 2016 ... this year we rebranded our company as Sangamo ... genomic therapies using our industry leading platform technologies ... cell therapy," said Sandy Macrae , CEO ...
(Date:2/28/2017)... , February 28, 2017 The ... for assessment are the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ... AUPH ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... companies belong to the Healthcare sector, which was narrowly mixed ... Health Care Index declining less than 0.1%, while shares of ...
(Date:2/27/2017)... , February 27, 2017 A Europe-wide ... indicated that researchers using animals in their research treat them with ... 26 countries, and detailed analysis of the results indicates that there ... to put into practice the principles of the 3Rs ... ...
(Date:2/27/2017)... CITY, Calif. , Feb. 27, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced today the U.S. Food and ... Drug Application (NDA) under section 505(b)(2) for DSUVIA™ ... the treatment of patients with moderate-to-severe acute pain ...
Breaking Biology Technology: